More than 500 unrelated patients with neurofibromatosis type 1 (NF1) were screened for mutations in the NF1 gene. For each patient, the whole coding sequence and all splice sites were studied for aberrations, either by the protein truncation test (PTT), temperature-gradient gel electrophoresis (TGGE) of genomic PCR products, or, most often, by direct genomic sequencing ( 
Introduction
Neurofibromatosis type 1 (NF1; also known as "von Recklinghausen neurofibromatosis" [MIM 162200]) is a common autosomal dominant disorder affecting ∼1 per 3,000-5,000 people. It is fully penetrant and exhibits a mutation rate some 10-fold higher than that reported for most other disease genes. As a consequence, a high number of sporadic cases (up to 50%) is observed (Upadhyaya and Cooper 1998) . NF1 is clinically characterized by cutaneous neurofibromas, café-au-lait spots, iris hamartomas (Lisch nodules), and freckling of axillary and inguinal regions. These features are present in 190% of patients at puberty. Further manifestations, such as deeply situated and arbitrarily located neurofibromas, plexiform neurofibromas, optic glioma, macrocephaly, short stature, learning difficulties, scoliosis, and pseudarthrosis, as well as certain malignancies, occur less frequently among patients with NF1 (Riccardi 1992; Huson and Hughes 1994; Friedman and Birch 1997) . NF1 is notable for its extreme phenotypic variability, both within and between families (Riccardi 1992) . In addition to multiple allelism of the NF1 locus, the influence of modifying genes (Easton et al. 1993 ) and the impact of stochastic events (Riccardi et al. 1993 ) have been suggested as causes of this variability. So far, none of these hypotheses has been tested satisfactorily. A comprehensive analysis of the mutational spectrum might help to elucidate the role of different NF1 mutations.
The NF1 gene maps to chromosome 17q11.2 and is considered to be a tumor-suppressor gene, because lossof-function mutations have been associated with the oc- Purandare et al. (1995) .
b Two different annealing temperatures (T a ) connected with an arrow indicate a touch-down PCR protocol with the first 8 cycles being performed at the higher temperature.
currence of benign and malignant tumors in neuralcrest-derived tissues (Legius et al. 1993; Colman et al. 1995; Serra et al. 1997) as well as myeloid malignancies (Shannon et al. 1994 ). The NF1 gene was cloned in 1990 (White and O'Connell 1991) . It spans over 350 kb of genomic DNA comprising у60 exons. The openreading frame codes for 2,867 amino acids, including three alternatively spliced exons. The most common transcript codes for a polypeptide of 2,818 amino acids called neurofibromin (Marchuk et al. 1991; Danglot et al. 1995; Li et al. 1995) . A central region of about 360 amino acids shows significant homology to the mammalian GTPase-activating protein (GAP) ). This region, the NF1 GAP-related domain (GRD), is encoded by the exons 20-27a and has been found to interact with p21 ras (Martin et al. 1990) . As a result of this interaction, GTP•Ras levels may be elevated in human NF1 peripheral nerve tumors, in which neurofibromin is usually found to be totally absent or, at least, dramatically reduced (Guha et al. 1996) . Commensurate with its pivotal functional significance, several missense mutations were identified in the GRD (Li et al. 1992; Upadhyaya et al. 1997; Kim and Tamanoi 1998; Klose et al. 1998a) .
In general, mutation analysis of the NF1 gene has turned out to be a major challenge, for several reasons. The large size of the gene under investigation and the diversity of the underlying pathological lesions (Korf 1998; Upadhyaya and Cooper 1998) make analysis problematic. In addition, the presence in the genome of several unprocessed NF1 pseudogenes severely hampers PCR approaches to the analysis of genomic DNA samples, because of coamplification of homologous sequences of the NF1-like loci at other chromosomes (Purandare et al. 1995; Régnier et al. 1997) . Most of the NF1 mutations are point mutations or other small lesions leading to premature termination codons (PTCs) (Upadhyaya and Cooper 1998) . Hence, the application of the protein truncation test (PTT) was thought to substantially accelerate the rate of identification of NF1 mutations. In an initial study, mutations were identified in 14 (67%) of 21 individuals (Heim et al. 1995) . Before PTT was introduced, the best results had been obtained by using chemical mismatch cleavage analysis. In a study covering 70% of the coding sequence, seven mutations were found in 25 patients (28%) (Purandare et al. 1994) . In a more recent study, by using a combined heteroduplex/SSCP approach, researchers identified only 13 disease-causing mutations in 67 unrelated NF1 patients (a 19% detection rate), even though as many as 45 exons were tested (Abernathy et al. 1997) . Most other analyses focused on one or a few arbitrarily selected exons but sometimes were performed in very large cohorts of NF1 patients (e.g., Maynard et al. 1997) .
Together with multiple reports of isolated mutations, b Psoralen modification is indicated by "p-"; note that psoralen is followed by two adenosine residues irrespective of the target sequence. c T a is the annealing temperature for the primers during PCR. d The exons 28 and 29 were investigated by single-strand conformation polymorphism (SSCP) analysis in lieu of TGGE (see Peters et al. [1999b] ).
e A second TGGE analysis of exon 4a was performed after digesting the PCR product with Tru 9 I. most of these data have been submitted to the NF1 Genetic Analysis Consortium. The consortium was organized in the autumn of 1992 to facilitate mutation detection in the NF1 gene and to pool mutation data into a common database for better interpretation of the growing body of information. By November 1997 a total of 240 mutations, including 173 minor lesions (72%) had been reported to the consortium (Korf 1998 ). The mutational spectrum obtained from these data, however, suffers from a strong bias towards more thoroughly investigated regions of the NF1 gene. To overcome this drawback, we launched a mutationscreening project in Germany aimed at the complete analysis of the entire NF1 gene in a large cohort of unrelated NF1 patients. According to the preferences of the participating centers, PTT, temperature-gradient gel electrophoresis (TGGE) analysis (Riesner et al. 1989; Wartell et al. 1990) , and direct genomic sequencing (DGS) of all individual exons were used for our analysis.
Materials and Methods

Patient Samples
The study was approved by the ethics committee of the Charité University Hospital. NF1 diagnostic criteria b T a is the annealing temperature for the primers during PCR. (Gutmann et al. 1997 ) were used to identify 521 unrelated patients with NF1, all of whom were of German or Turkish descent. Once informed consent was obtained, DNA from peripheral blood was obtained from each patient, applying one of several standard procedures. RNA was also obtained from some patients, either from fresh blood or from cell cultures (i.e., fibroblastlike cells or Epstein-Barr virus-transformed lymphocytes) by using the RNeasy total RNA purification kit (Qiagen). The SuperScript preamplification system (BRL Gibco) was used to prepare cDNA from the RNA samples. The cDNA reaction was performed in a 20-ml reaction volume containing 2-3 mg total RNA, 1.5 mg random hexamers (BRL Gibco), 0.5 mg single-stranded binding protein (Promega), 20 units RNAsin (Promega), 4 mM each dNTP, and 300 U Superscript II reverse transcriptase (RT) (BRL Gibco). cDNA was stored at -20ЊC.
Analysis of NF1 Gene Expression
Allele-specific expression level studies were performed by RT-PCR reactions by using the following primer pair to amplify the polymorphic exon 5 (Hoffmeyer and Assum 1994) from cDNA: 5 -TAGTCGCATTTCTAC-CAGGTTA-3 (sense primer) and 5 -GAGAATGGCT-TACTTGGATTAAA-3 (antisense primer). Thirty PCR cycles of 1 min at 92ЊC, 1 min at 54ЊC, and 1 min at 72ЊC were used. After RsaI restriction, the fragments were analyzed by agarose gel electrophoresis and ethidium bromide staining. Subsequently, the band intensities were measured densitometrically by using a chargecoupled-device camera and the ImageQuant software package distributed with the Phosphoimager from Molecular Dynamics.
PTT
RT-PCR.-Hot-start PCR reactions to amplify each of the five overlapping segments required that 2.5-3 ml cDNA be added to a lower-phase PCR mixture containing 1# PCR buffer (50 mM KCl, 10 mM Tris, pH 8.3, and 2 mM MgCl 2 ), 0.8 mM each dNTP, and 10 pmol each primer (primer sequences were as described elsewhere (Heim et al. 1995) in a total volume of 40 ml. A wax gem (Perkin Elmer) was added to each tube. Reaction mixtures were heated to 80ЊC for 5 min, followed by cooling to room temperature. A 10-ml upperphase mixture containing 1# PCR buffer, 0.25 mg single-stranded binding protein, and 2.5 units Taq polymerase (Pharmacia) was layered onto the solidified wax. Reactions were performed in a Cetus model 9600 thermal cycler (PE Biosystems), under the following conditions: 95ЊC for 1 min; 40 cycles of 95ЊC for 30 s, 61.5ЊC for 30 s, and 72ЊC for 90 s; and 72ЊC for 10 min. The PCR products were analyzed by agarose gel electrophoresis. Apparent splice defects, for example, exon skipping events, were verified by cDNA sequencing by using radioactive labeling and the Thermo Sequenase kit (Amersham Life Science). Subsequently, the presumably mutated exons or exon/intron boundaries were sequenced from the patients' genomic DNA samples.
In vitro transcription/translation and analysis of the peptides.-For each in vitro transcription/translation reaction, 4-9.5 ml PCR product (volume depends on the quality of the PCR product) and 0.5 ml 35 S-methionine (specific activity: 11000 Ci/mmol; Amersham) were added to the commercially available TNT TM Coupled Reticulocyte Lysate System (Promega). Reactions were performed under conditions recommended by the manufacturer, with 1 exception: for all components, only a one-half volume was added to the PTT reaction (e.g., 12.5 ml TNT Rabbit Reticulocyte Lysate). After incubation of the complete reaction for 1.5 h at 30ЊC, 5 ml of the reaction was added to 5 ml loading buffer (10% glycerol, 5% 2-mercaptoethanol, 2% SDS, and 0.1% bromphenol blue), and was heated for 5 min, then placed on ice. Samples were subjected to electrophoresis in a 14% SDS-polyacrylamide gel for 1.5-2 h at 40 mA (Rainbow 14 C methylated protein (Amersham) was used as a protein-weight marker). The gel was fixed in a solution of 40% methanol and 10% acetic acid and dried for 1.5 h at 80ЊC in a gel dryer. The synthesized polypeptides were visualized by means of a Phosphoimager (Molecular Dynamics) after the gel had been exposed overnight to a special film slide (Molecular Dynamics). On the basis of the determined fragment size, the positions of the mutations causing shortened polypeptides in the PTT were predicted and the presumably affected exons were sequenced from the patient DNA samples. Either the Thermo Sequenase kit (Amersham Life Science) and radioactive labeling were used for DNA sequencing or samples were analyzed on an ABI 377 PRISM DNA Sequencer by using the Big Dye terminator chemistry (see below).
TGGE
For TGGE analysis, the individual NF1 exons were usually amplified directly from genomic DNA. For several exons, however, preamplification of a larger genomic fragment was necessary (see table 1) to improve specificity-that is, either to avoid coamplification of NF1 pseudogenes or simply to relieve constraints of TGGE primer design. Final TGGE primers were chosen by using the programs MELT87 and SQHTX (Lerman and Silverstein 1987) , which allow prediction of the impact of mutations on the melting behavior of the PCR products. Sequences containing two or more melting domains were split into several overlapping fragments. One or both oligonucleotides of each primer pair were 5 -modified with psoralen (table 2). Using two psoralenmodified primers in one reaction results in bipolar clamping of the fragments that may improve the sensitivity of mutation detection (Gille et al. 1998 ). For PCR, some 100 ng of genomic DNA (for the nested PCRs, 50 ng PCR product is required) were added to 25 ml standard Perkin Elmer PCR buffer containing 1.5 mM MgCl 2 , 200 mM each dNTP, 0.2 mM each primer, and 0.5 U Taq polymerase. All reactions were performed on a Perkin Elmer thermocycler (model T1), under the following conditions: 95ЊC for 3 min; 35 amplification cycles of 95ЊC for 30 s, specific annealing temperature T a (seetable 2) for 30 s, and 72ЊC for 50 s (final extension for 10 min). A commercially available apparatus was used for TGGE (Diagen GmbH, Germany). Prior to electrophoresis, the PCR products were placed directly under a portable UV light source (365 nm) for 15 min to permit cross-linking of the psoralen moiety to the thymine residues of the opposite DNA strand. For exons 2-49, TGGE was done on an 8% polyacrylamide gel with 8 M urea in 3-N-morpholino-propanesulfonic acid (MOPS) buffer. For exon 1, an 8% polyacrylamide gel with 7 M urea and 35% formamide in MOPS buffer was used. The individual running conditions for each exon are given intable 2. Silver staining was used for visualization of bands. Samples that showed altered mobility patterns were subjected to DNA sequencing, as described below. Alternatively, radioactive labeling and the Thermo Sequenase kit (Amersham Life Science) were used for sequencing.
DGS
For DGS-PCR, samples were cycled with a first activating step for HotStarTaq (Qiagen) at 95ЊC for 3 min. Primer sequences, fragment sizes, and annealing temperatures are given in table 3. Each cycle consisted of a denaturation step at 95ЊC for 90 s, annealing for 40 s (48ЊC to 65ЊC, see table 3) and an extension step for 1 min at 72ЊC. 35 cycles were performed in a 20-ml reaction volume on a 9700 thermal cycler (PE Applied Biosystems). PCR products were purified by using the PCR Product Purification Kit (Qiagen) according to the manufacturer's protocol. Cycle sequencing was performed in a 5-ml volume at 60ЊC with 25 cycles. Sequencing products were purified on Sephadex G-50-80 columns (Sigma) and analyzed on an ABI 377 automated DNA sequencer (PE Applied Biosystems).
Results
Synopsis of Mutation Screening
We analyzed 521 unrelated patients with NF1 by means of PTT, TGGE, or DGS for mutations in the whole coding sequence and the splice sites of the NF1 gene. Twenty patients were included in both the PTT and the TGGE screening program. In total, we identified 301 sequence changes (table 4), 278 of which were considered pathogenic. The detection rates for the different methods were 40/85 (47.1%) for PTT, 65/121 (53.7%) for TGGE, and 184/335 (54.9%) for DGS. The mutations of 11 patients were identified independently by PTT as well as by TGGE. Among the 278 mutations identified, we observed 84 (30.2%) nonsense mutations and 140 (50.4%) frameshift mutations, comprising 78 deletions and 32 insertions of one or a few base pairs, as well as 30 out-of-frame exon skipping events. Thus, as many as 224 (80.6%) mutations caused, directly or indirectly, a premature termination codon (PTC). Another 25 (9.0%) of the mutations caused in-frame exon skipping. Furthermore, 28 (10.1%) missense mutations and one initiation codon mutation were also observed. Most mutations were found only once in any one pa- b Numbering system based on NF1 cDNA (Genbank M82814), 1 = first base of methionine (ATG) at start of cDNA. The asterisk indicates congruence to NF1 pseudogene sequences: C910T to D26141/AC004527 (#21); C2041T to U35696 (#14); A3467G, C3721T, C3826T, and C4537T to M84131 (#15).
c All GrA and CrT transitions were checked to see whether they occurred in a CpG or a CpNpG motif. In the latter case, "yes" was put in parentheses.
d A question mark in parentheses means "predicted but not tested." A question mark without parentheses means "highly speculative" and that the underlying mutations were not considered pathogenic.
e In the case of frameshift mutations, the affected amino acid (aa) positions are given, as well as the position of the premature termination codon (PTC) in the predicted aberrant polypeptide. In the case of in-frame deletions caused by exon skipping, the number of amino acids (aa) expected to be lost in the predicted aberrant polypeptide is given.
tient. The total number of different mutations identified was 216. Among the recurrent mutations, the three most common were R1513X in exon 27a (7 patients), 499delTGTT in exon 4b (6 patients), and 6789delTTAC in exon 37 (five patients). Furthermore, we found that 216 of our mutations, of which 179 were different, were not listed in the most recent review in the field (Upadhyaya and Cooper 1998). Overall, the total number of different minor lesion mutations of the NF1 gene described to date well exceeds 276, because 97 other mutations of this type have been published before (Upadhyaya and Cooper 1998) and some more unpublished mutations have been reported to the International NF1 Genetic Analysis Consortium.
Distribution of NF1 Mutations
To get an idea of their distribution over the NF1 gene, we plotted the 278 pathogenic mutations exon by exon into a diagram ( fig. 1) . Intronic mutations were allocated to the nearest exon. Direct comparison with the 173 minor lesions that had been reported to the International NF1 Genetic Analysis Consortium by November 1997 (Korf 1998 ) (white columns in fig. 1 ) underscores the strong bias towards central parts of the NF1 gene inherent in these data. In particular, exons 28-36-the 9 exons that were described first )-and the GRD region were analyzed in hundreds of NF1 patients by the consortium members, whereas exons of other regions, mainly at the 5 end of the gene, were not investigated at all. In our study, all parts of the gene were analyzed with equal intensity. Thus, we suppose our data to be an approximate representation of the actual distribution of mutations over the NF1 gene, at least in our study population, which is mainly of German origin, but includes also some patients of Turkish extraction. As indicated by figure 1, it appears likely that all regions of the NF1 gene are subject to mutation to a similar extent. However, if data are weighed for exon size ( fig. 2a) , exons 4b and 37 stand out as sites of a remarkably high mutation density. The reason for this may be found in some structural elements prone to mutation, a short tandem repeat structure in exon 4b (Toliat et al. 1999 ) and a quasisymmetric element in exon 37 (Robinson et al. 1995; Bö ddrich et al. 1997) .
Figure 1
Histogram of number of mutations, exon by exon. Black columns represent the 278 pathogenic mutations of table 4. White columns represent the mutations reported to the NF1 Genetic Analysis Consortium as of November 1997 (Korf 1998) .
If presented in a logarithmic mode ( fig. 2b) , the data reveal a slight tendency to fewer mutations towards the 3 end of the gene that may be caused by the distribution of the missense mutations, as discussed later. Furthermore, several exons are easily recognized in which no mutation was found (exons 9br, 19b, 23a, 38, and 48-49) or that are extremely underrepresented (exons 4a and 33).
Cryptic Splice Mutations
We identified a total of 55 splicing-error mutations (19.8% of all the mutations we found). In 22 cases, an exon skip was revealed in the patients' mRNA. Several mutations were found to affect the splicing process, although they do not pertain to the group of typical splicesite mutations. At first glance, many of these were interpreted as faults, but analysis of mRNA as part of the PTT made us aware of the problem, and we initiated a routine checking of mRNA in all ambiguous cases (if mRNA was available). As reported elsewhere (Hoffmeyer et al. 1998) , the two nonsense mutations (R304X and Y2264X) result in a skipping of exons 7 and 37, respectively. The mutation Y2264X may be caused by either of two transversions, C6792A or C6792G, both of which result in skipping of exon 37 (Messiaen et al. 1997) . Five other nonsense mutations, as well as six small deletions or insertions, were also tested thoroughly, but did not show any influence on the splicing process (see table 4). However, in addition to the nonsense mutations, we identified a silent mutation (K354K) and several missense mutations (Y489C, S574T, S574N, R1849Q, and A2420P) that also cause exon skipping, presumably or definitely (see table 4 ). Most of these mutations affect the last base of the exon that is part of the splice donor and is usually a guanine (Krawczak et al. 1992) . Messiaen et al. (1998) reported that mutation Y489C generates a new splice donor converting the 3 end of exon 10b into an intronic sequence that is subsequently removed during splicing as part of intron 10b. The mutation Y491C might act in the same manner; however, no mRNA was available to test this possibility.
Two Sequence Changes
All 60 exons were analyzed in all patients; therefore, multiple sequence changes should have been identified if present. In addition to the known biallelic polymorphisms in exons 5 (702A/G) and 13 (2034G/A) and those in introns 28 (5205ϩ23C/T) and 41 (7395-29A/G), we identified three novel biallelic polymorphisms: 1528-29delT, 1641ϩ39C/T, and 3315-130G/C (located in introns 10b, 10c, and 19b, respectively) with allele frequencies higher than 30% for both alleles. The frequent
Figure 2
Weighed distribution of mutations over the NF1 gene. For each exon, the number of pathogenic mutations was divided by the number of base pairs (bp). Ten bp were added to each exon, to allow for splice-site mutations. Values shown are ratios between the exonspecific mutation densities and the average mutation density for the whole gene (278/9,204 bp). A, linear presentation. B, logarithmic presentation.
polymorphisms were not taken into account when looking for additional sequence changes in the NF1 gene, yet two rare sequence changes were found in 10 of the patients (table 5) . Determining which change is pathogenic is straightforward if a truncating mutation is observed among them; however, the occurrence of two pathogenic mutations is possible. We tested the mutations 2252-31ArT and 8050ϩ20ArG for their influence on the splicing process, but no exon skipping was observed. In the case of patient 1899, a choice between two missense mutations, D176E and R1276Q, was necessary; the position of the latter gives a helpful hint. Arg1276 is the arginine finger of the GRD-the most essential catalytic element for RasGAP activity. Its mutation into proline was shown to completely disable GAP activity without impairing the secondary and tertiary protein structure (Klose et al. 1998a) . Mutation R1276Q compromises GAP-stimulated GTP hydrolysis some 500-fold (Ahmadian et al. 1997) . Compared with the 8,000-fold reduction by mutation R1276P (Klose et al. 1998a) , this is still a remarkable residual activity. However, it may be sufficient to cause NF1, because other missense mutations of the GRD with moderate reduction of GAP activity have already been reported (Kim and Tamanoi 1998) . It is tempting to speculate about a modifying effect of D176E on the NF1 phenotype. This might occur in cis as well as trans to another missense mutation or in trans to any other pathogenic mutation. In the instance of patient 1899, it is not known whether D176E and R1276Q are situated on the same allele or on different alleles. In the other three cases, both sequence changes cosegregate; that is, D176E is in cis to a truncating mutation, with little or no chance of exerting an effect on the phenotype because of the absence of the mutant gene product normally observed with this type of mutation (Hoffmeyer et al. 1995) . Recently, we analyzed the unaffected father of patient 702, who is a sporadic case himself. Because the father is also a carrier of D176E, we were able to determine that this amino acid exchange alone is not sufficient to cause NF1.
CpG Mutations
CpG dinucleotides show a high mutation rate in the human genome caused by spontaneous deamination of 5-methylcytosine; ∼25% of all single base-pair substitutions involve this dinucleotide (Cooper and Krawczak 1993) . In the coding region of the NF1 gene, there are 118 CpGs, and a CrT transition on either the coding or noncoding strand of 91 of these would result in a disease-related mutation (Krkljus et al. 1997) . Methylation of CpGs is a prerequisite for this type of mutation. Interestingly, methylated CpGs have been reported to occur within and around the NF1 gene; for example, 92% of CpGs in exons 28, 29, and 31 were found to be methylated in sperm DNA (Rodenhiser et al. 1993; Andrews et al. 1996) . This prompted us to check our data for typical CpG mutations. Among the 301 sequence changes, we identified 57 (18.9%) CrT or GrA transitions within a CpG dinucleotide (table 4). The 301 sequence changes include 181 single base-pair substitutions, and only 31.5% of these represent a typical CpG mutation. Twenty-one different CpGs from the coding region are involved; that is, 17.8% of the 118 CpGs present in the coding region. They include 1 silent, 2 missense, and 18 nonsense mutations. One of these CpG mutations, R1513X, is the most frequently observed recurrent mutation among all 278 mutations. In addition to CpGs, we identified 9 CpNpG motifs that were subject to a CrT or GrA transition in 10 patients. Although DNA methylation at these sites has also been reported (Clark et al. 1995) , it is evident from our data that they do not play a significant role in NF1 mutagenesis.
Relations to Pseudogene Variants
Genetic variation within pseudogenes may serve as a template for pathological lesions in the original gene by means of gene conversion even if located on different chromosomes (Eikenboom et al. 1994) . In view of the large number of NF1 pseudogenes, it has been hypothesized that they are reservoirs of preformed mutations and may account for the high mutation rate of the NF1 gene (Cummings et al. 1993) . Therefore, we analyzed all NF1-like sequences available from the public databases for any sequence deviation from the authentic NF1 gene. We located 31 entries (table 6) and identified 235 discrepancies (of which 196 were different) between the Table 6 sequences of the pseudogenes and the NF1 gene (not shown). Only 6 (3.1%) of the 196 pseudogene variations were also found among the NF1 mutations in table 4 (indicated by an asterisk); however, 4 of the 6 were recurrent mutations (including R1513X, which was found in seven patients). Unfortunately, all but 1 of the 18 mutations with a pseudogene equivalent happened to occur at highly mutable CpG sites (see above). This definitely weakens further the evidence of NF1 gene conversion. Moreover, for gene conversion to explain the high mutation rate, mutations should predominantly affect the central part of the gene, which is not the case.
Missense Mutations
Formally, we identified a total of 39 missense mutations or deletions of single amino acids. However, as discussed earlier, D176E has to be considered a polymorphism, and others were shown to be splice mutations. Furthermore, substitution of threonine for the first methionine will cause a false start in translation, with one of the following methionines acting as the initiation codon (Neote et al. 1990; Patten et al. 1990 ). Hence, strictly speaking, only 28 are genuine missense mutations causing changes or losses of a particular amino acid in the polypeptide chain. The distribution of these mutations is shown in figure 3 . It is evident that the mutations cluster in two regions: the GRD, and upstream between exons 10b and 17. If we assume the mutation Y491C to be a splice mutation like Y489C (see above), this region would shrink even further, to an interval from exon 11 to exon 17. Interestingly, a total of 11 substitutions into proline (39%) were found among the 28 missense mutations. Proline is known to destabilize helices and beta sheets.
Except for patient 1899, who carries two missense mutations, R1276Q and D176E, all of the other 28 genuine missense mutations turned out to be the only sequence change present in the entire NF1 gene. This sug-
Figure 3
Weighed distribution of missense mutations over the NF1 gene. For each exon, the number of genuine missense or single-aminoacid-deletion mutations was divided by the number of base pairs (bp). Values shown are ratios between the exon-specific mutation densities and the average mutation density for the whole gene (28/8457 bp). Location of the GRD is indicated by the box.
gests that these mutations cause the disease, yet further evidence is needed to verify this hypothesis. To date, functional and structural assessment of particular amino acids has been obtained only for the GRD. For other regions, information about evolutionary conservation may help to evaluate the significance of an amino acid exchange. Therefore, we generated an amino acid sequence alignment (program PILEUP of the GCG-Wisconsin package, version 9; gap weight 12 and gap length weight 4) between the sequences of the human and the Drosophila NF1 proteins that are 60% identical over their entire length . As many as 15 of the 23 amino acid positions affected by missense mutation in our patients with NF1 turned out to be invariant, whereas, at two further positions, the amino acids were replaced by similar ones in the Drosophila protein (Ile1584 by Val and Arg1250 by Lys). At the other six positions nonconservative substitutions were found or the alignment generated a gap in the Drosophila protein (Y491: M; K583: Q; S665:Ϫ; H781: F; M1215: I; T2486:Ϫ). Moreover, we performed a similarity plot between the human and Drosophila sequences. Most of the mutations are situated on top of the similarity peaks or, at least, in regions of higher similarity, which may represent helices or beta sheets (fig. 4 ). Exceptions are Y491C-which might, in fact, be a splice mutation-S665F, and T2486I. These findings raise the possibility that the latter two mutations may actually be nonpathogenic.
Discussion
The systematic analysis of germline mutations in NF1 patients has been a major challenge for many laboratories during the last couple of years. Here, we present for the first time a comprehensive screen of minor lesions of the NF1 gene in a large cohort of 1500 unrelated patients that is free of any assessment bias for special exons or regions. We launched this project hoping that the data would allow us to answer some long-standing questions about the NF1 gene and its proneness to mutate. Some of the questions were answered, but new questions were raised as well.
The Mutational Spectrum
A preponderance of truncating mutations is one of the most prominent features of NF1 mutations. Some 80% of all small lesions result in a PTC; that is, about one half of all NF1 mutations may be direct-or indirect-
Figure 4
Missense mutations in the similarity plot of human versus Drosophila NF1 protein. The program PLOTSIMILARITY of the GCG-Wisconsin package, version 9 was used to calculate the amino-acid-sequence similarity profile of the human and Drosophila neurofibromins (accession numbers AAA59925 and AAB58976, respectively). A sliding window of 40 amino acids was chosen. Note that there are 2,963 instead of 2,839 amino acid positions in the alignment (program PILEUP; gap weight = 12 and gap-length weight = 4). For the first 20 and the last 20 positions, a value could not be calculated, because of the chosen window size. Mutations are located primarily in regions of higher similarity. Usually, helices and beta sheets have a higher local sequence similarity than coils. stop mutations. Distribution of this type of mutation is very even over the coding sequence. We identified the first one in exon 1 and the last in exon 47. At first glance, no difference in phenotype was observed; however, a detailed analysis of a possible relation between clinical features and position of the PTC is in progress and will be presented elsewhere (S. Tinschert, A. Buske, B. Mü ller-Myhsok, I. Naumann, C. Mischung, R. Fahsold, S. Hoffmeyer, D. Kaufmann, H. Peters, P. Nü rnberg, unpublished data). Unequal expression of both NF1 alleles is a common observation in NF1 and has been related to the high number of truncating mutations (Hoffmeyer et al. 1995) . This might explain the absence of a position effect of PTCs; however, we also observed equal expression in some cases, including patients U-62, 82, 342, and 407 (table 4) . Of all mutations identified in this study, ∼20% were splice defects, with nearly onehalf of the latter causing in-frame exon skipping. Hence, analysis of mRNA, in combination with a PTC screening as performed in the PTT, is a good choice for mutation detection in NF1. In our hands, the detection rate was 47.1%, which is lower than the 67% detection rate originally reported (Heim et al. 1995) but in line with the genomic-screening methods applied in this study, taking into account the fact that missense mutations cannot be detected by this approach. According to our data, missense mutations represent ∼10% of all small NF1 lesions.
The identification of a recurrent NF1 mutation has often been heralded as the discovery of a mutation hotspot. The most widely known example is the mutation R1947X in exon 31 (Valero et al. 1994; Lá zaro et al. 1995) . At least 10 unrelated patients with NF1, among 563 tested, were reported to carry this mutation (recurrence rate ∼2%) (Upadhyaya and Cooper 1998) . In our screening of 521 unrelated patients with NF1, however, only 3 presented with this mutation. The most frequent mutation in our study was R1513X in exon 27a found in seven patients. However, when looking for the highest density of mutations, exons 4b and 37 outnumbered all other exons with a value 4-to 5-fold higher than average. This suggests these exons include some minor hotspots. Nevertheless, with the large number of novel mutations presented in this paper, it becomes obvious that
Figure 5
Synopsis of all known NF1 missense mutations and deletions of 1 or 2 amino acids. Mutations on the left and right sides are data from this study and from the literature, respectively. Most published mutations have been reviewed in Upadhyaya and Cooper (1998) . Some have been published very recently: R1204G (Krkljus et al. 1997 ); C39Y(1), Y489C, L847P, and 991delM(1) (Messiaen et al. 1998) ; and L2317P (Wu et al. 1999) . Others have been submitted to the consortium but not published at this time. They are reported here with the consent of the consortium members who identified these mutations: 2366delNF(2) and R2616Q (L. Messiaen, personal communication); R1849G and L1932P (M. Upadhyaya, personal communication); 1658delIY and P2046R (D. Vidaud, personal communication). Mutations not representing genuine missense mutations including polymorphisms, splice mutations, or loss of the initiation codon are printed in italics. Number in parentheses after the mutation symbol indicates recurrent identifications. GRD region is shown in gray, whereas the exons 11-17, supposed to code for a new functional domain, are shown in black with a central light effect. To facilitate orientation, the numbers of some of the larger exons are given.
the worst-case scenario is operating: hundreds of private mutations for most of the families affected by NF1. Interestingly, all three alternatively spliced exons-9br, 23a, and 48a-seem to be irrelevant to mutation analysis. Likewise, two normally spliced exons-19b and 38-also failed to show a mutation in our study population, and other exons-such as 4a and 33-harbored only a single mutation. The reason for this underrepresentation in the compulsory exons is not clear and may be purely accidental. For exons 33 and 38, additional mutations have been reported to the consortium (Korf 1998) .
In general, the mutational spectrum of the NF1 gene seems to be very similar to that of other tumor-suppressor and mutator genes, which all seem to be characterized by a large proportion of truncating mutations-for example, nearly 100% for APC (Suzuki et al. 1998) and TSC1 (Jones et al. 1999) , 180% for RB1 (Lohmann et al. 1996; , ∼80% for BRCA1 (Miki et al. 1994) and ATM (Sandoval et al. 1999) , and ∼60% for TSC2 (Jones et al. 1999) , and all six NBS1 gene mutations identified to date (Varon et al. 1998 ). Similarly, 5%-20% missense mutations, as well as wholegene deletions, have been found in some of these genes (RB1, ATM, TSC2). In addition, the problem of unsuccessful mutation detection in many of the patients is common to all these genes. Little more than half of all the NF1 alleles investigated in this study yielded a detectable mutation. It is true that the PTT protocol used here might have failed to detect missense as well as splicing-error mutations-especially those that result in inframe skips of small exons-but, in most cases, all exons and adjacent intron regions of the NF1 gene were sequenced. DGS, like TGGE, is commonly thought to provide a sensitivity close to 100% in the analyzed regions, and, although some problems with heterozygote detection in automated sequencing are known to impair the identification rate of point mutations, this alone is unlikely to account for missing 140% of the NF1 mutations. Some of the unidentified mutations are definitely large deletions comprising the whole NF1 gene or a major part of it. When analyzing 15 TGGE-negative cases by fluorescence in situ hybridization, we identified three NF1 gene deletions (G. Thiel, unpublished data). Hence, we estimate the overall proportion of gross genomic deletions to be ∼10%. Among the remaining 35% of undetected mutations, multiexon deletions may represent the largest group (15% of all mutations, according to the consortium data [Korf 1998 ]). Furthermore, large duplications or inversions would also have escaped our PCR-based mutation scanning (Naylor et al. 1993) . Incomplete assessment of intronic and regulatory sequences probably accounts for other unidentified cases. However, NF1 promoter mutations seem to be rare and the sequence variants identified so far are unlikely to cause the disease phenotype (Osborn and Upadhyaya 1998) . For the RB1 gene, silencing of the promoter by allele-specific hypermethylation of a CpG island in the 5 region was shown in 10% of retinoblastomas (Sakai et al. 1991; Greger et al. 1994) . Interestingly, a hypomethylated region near the transcription start site within the NF1 CpG island could act as a target for silencing of the NF1 gene by local hypermethylation (Rodenhiser et al. 1998 ). Thus, epigenetic and genetic mechanisms may cause inactivation of NF1 transcription. Recent studies have shown that somatic mosaicism may be a frequent finding among sporadic cases of NF1 (Colman et al. 1996; Ainsworth et al. 1997; Tonsgard et al. 1997; Wu et al. 1997; Rasmussen et al. 1998) . Provided the mutation was present in the tissues analyzed, the methods used for exon screening in this study are unlikely to have had sufficient sensitivity to detect low-level mosaicism. Unfortunately, we cannot exclude the possibility that patients who did not have NF1 were included in the screening, because some of the patients were diagnosed by others. Finally, the existence of genetic heterogeneity in NF1 is still an open discussion.
High Mutation Rate
The mutation rate for NF1 is one of the highest known for human disorders, estimated to be between 1#10 Ϫ4 and 3.1#10
Ϫ5 (Sergeyev 1975; Huson et al. 1989; Clementi et al. 1990 ). Thus, the NF1 gene seems to mutate 10 times more often than other disease genes. Several reasons have been proposed to explain the high mutability of the NF1 gene, including its relatively large size of ∼350 kb, gene-conversion events via pseudogenes, and mutational hotspots. Acting on the results of our study, we can definitely exclude the many NF1 pseudogenes as a major reason. Furthermore, pronounced hotspots of mutation have not yet been identified in the NF1 gene. It is true that some of the recurrent mutations, such as R1513X and R1947X, affect CpG dinucleotides, but the overall proportion of CrT or GrA transitions within CpGs is as low as 19% of all mutations and 32% of all the single-base-pair substitutions. Many other genes show similar or even higher percentages of CpG mutations-for example, 46% of factor VIII point mutations in hemophilia A (Antonarakis et al. 1995) , 45%-50% of TP53 point mutations in colorectal cancer (Greenblatt et al. 1994) , and 20%-25% of all RB1 mutations (Cowell et al. 1994) . Likewise, overlap between pseudogene sequence variants and NF1 germline mutations as identified in this study is negligible. Therefore, we assume the large size of the NF1 gene to be the major reason for the high mutation rate, which is in fact not considerably higher than that of other large genes. In Duchenne muscular dystrophy, which is caused by mutations in an even larger gene (79 exons in 2.5 Mb), a similar high mutation rate is found (Vogel and Motulsky 1997) . Interestingly, current estimates in Marfan syndrome place its prevalence at 1 per 3,000-5,000 people (Pyeritz 1996) . This suggests that the FBN1 gene (65 exons in 110 kb), which is very similar in size to the NF1 gene, has a mutation rate nearly as high as in NF1.
Second Functional Domain
Our characterization of significant numbers of missense mutations and some small in-frame deletions is likely to be helpful in the investigation of putative functions of the NF1 gene product. The RasGAP activity of the central GAP-related domain and the structure of the GRD from neurofibromin have already been well characterized (Kim and Tamanoi 1998; Scheffzek et al. 1998) , in particular, the effects of mutations of the arginine finger (Arg 1276) were studied in detail (Ahmadian et al. 1997; Klose et al. 1998a ). Clustering of missense mutations in the GRD, as observed in this and other studies ( fig. 5 ), is what we could expect from its functional relevance. However, there is another segment in the NF1 gene, upstream of the GRD, that harbors numerous missense mutations as well (see fig. 5 ). We assume this region defines a second functional domain of the neurofibromin molecule. Interestingly, this region coincides with the cysteine/serine-rich domain (CSRD) defined by Izawa et al. (1996) . The CSRD comprises amino acid residues 543-909, in which three cysteine pairs (residues 622/632, 673/680, and 714/721) may be comparable to those that Maru et al. (1991) suggested form the ATP-binding domain of BCR protein. Furthermore, this sequence harbors three potential cAMPdependent protein kinase A (PKA) recognition sites (Marchuk et al. 1991) . These are, indeed, subject to phosphorylation by PKA (Izawa et al. 1996) , and one is mutated in two of our NF1 families (mutation K583R in exon 12a). A second is situated in a small region (residues 815-834) of sequence similarity with two other proteins (MAP-2 and tau) that also associate with microtubules. It has been speculated that phosphorylation of this region might regulate the association of neurofibromin and microtubules (Gregory et al. 1993 ). The functional significance of the phosphorylation of neurofibromin by PKA is still unclear, but in view of the compelling evidence for the involvement of neurofibromin in cAMP-mediated signaling from Drosophila (Guo et al. 1997; , it may explain the observed link between the second messenger cAMP and the Ras signaling pathway (Wu et al. 1993) .
In summary, we have attributed functional relevance to a new region of the neurofibromin molecule on the basis of the missense mutations identified in a large cohort of NF1 patients. This protein segment was found upstream of the GRD and may be identical with the CSRD described elsewhere (Izawa et al. 1996) . PKA phosphorylation sites within the domain suggest this region might be involved in cAMP-mediated signaling. However, further studies will be required to substantiate our hypothesis. To this end, the functional significance of the relevant missense mutations is currently being tested in the Drosophila model.
